Recent studies indicate that IL-13Rα2 and EGFRvIII expression is significantly heterogeneous in glioma tissues, suggesting that strategies targeting both antigens simultaneously could achieve broader tumor coverage. This evidence concerns the gene IL13RA2 and neoplasm.